Centerphase (Upper Saddle River, NJ) has entered into a collaboration with Mayo Clinic to speed the introduction of new medical treatments developed by the biopharmaceutical industry. The Company address the root causes historically plaguing the clinical trials process: the lack of a systematic, structured approach for evaluating and optimizing protocols and the tremendous burdens associated with trial start-up administration.
Clinical testing of new medical therapies is an arduous process, which is difficult to plan, costly and habitually delayed. The industry spends over $30 billion a year on clinical trials, yet nearly 90% of trials fail to meet their timelines or budgets. The result has been longer delivery times and great disappointment among patients researchers and clinical trial sponsors.
As part of the new agreement, Mayo Clinic will access its Enterprise Data Trust (EDT) to provide Centerphase de-identified patient information to perform protocol review and optimization and help identify Mayo patients that potentially qualify for enrollment in a specific clinical trial. Mayo Clinic’s Enterprise Data Trust (EDT) is a secure collection of data on over 7 million patients from health records, education, research and administrative systems, organized to support information retrieval, business intelligence, and high-level decision-making.
“Centerphase will benefit from the intensive work Mayo has invested over the years in the development of a state of the art patient record health information system. This system, the EDT, will be leveraged by Mayo informatics experts who will conduct a rapid database review of potential Mayo patients qualifying for enrolment into clinical trials” says Jean-Pierre Kocher, PhD, Chair of the Division of Biomedical Statistics and Informatics.
Mayo Clinic is a minority equity owner in the new company.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.